Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06787612 · ClinicalTrials.gov registry record · Phase 2
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
A Phase 2 study of Ovarian Cancer, sponsored by Regeneron Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 220
- Enrollment target
- 20
- Study locations
NCT06787612: Recruiting Phase 2 study of Ovarian Cancer, sponsored by Regeneron Pharmaceuticals.
NCT06787612 is a Phase 2 study of Ovarian Cancer that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 220 participants, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (70% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06787612, a Phase 2 study of Ovarian Cancer, is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 220 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is researching an experimental drug called ubamatamab, also referred to as "study drug". The study is focused on patients who have advanced ovarian cancer. The aim of the study is to see how safe, tolerable, and effective the study drug is on its own and in combination with other anti-cancer drugs (bevacizumab, cemiplimab, fianlimab and a standard chemotherapy drug, pegylated liposomal doxorubicin \[PLD\]), referred to as "combination drugs'. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug and its experimental combinations * How much study drug and fianlimab is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects) and its combinations
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Cemiplimab
- DRUG PLD
- DRUG Ubamatamab
- DRUG Fianlimab
Study Locations (20)
Florida
- Mayo Clinic Jacksonville - Jacksonville
- University of Miami Sylvester Comprehensive Cancer Center - Miami
- Tampa General Hospital Cancer Institute - Tampa
California
- UC San Diego Health - La Jolla
- Cedars Sinai Medical Center - Los Angeles
Gyeonggi-do
- National Cancer Center - Gyeonggi-do
- Seoul National University Bundang Hospital - Seongnam-si
Alabama
- The University of Alabama at Birmingham - Birmingham
Illinois
- University of Chicago - Chicago
Kansas
- The University of Kansas Cancer Center - Westwood
Kentucky
- Norton Cancer Institute, St. Matthews Clinic - Louisville
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2025-05-28 |
| Est. Completion | 2028-12-07 |
| Phase | Phase 2 |
What NCT06787612 shows while recruiting
NCT06787612 is an interventional study that assigns participants to a tested intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 5 interventions - of which Bevacizumab is the first listed.
NCT06787612 names 20 study sites across 16 states, led by Florida, California, Gyeonggi-do.
Frequently Asked Questions
What is clinical trial NCT06787612 about?
NCT06787612 is a clinical study titled "Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer". This study is researching an experimental drug called ubamatamab, also referred to as "study drug". The study is focused on patients who have advanced ovarian cancer. The aim of the study is to see how safe, tolerable, and effective the study drug is on its own and in combination with other anti-ca...
What is the current status of trial NCT06787612?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 220 participants. The study started on 2025-05-28. Estimated completion is 2028-12-07.
What conditions does trial NCT06787612 study?
This clinical trial studies the following conditions: Ovarian Cancer.
What interventions are being tested in trial NCT06787612?
The interventions under investigation include: Bevacizumab (DRUG), Cemiplimab (DRUG), PLD (DRUG), Ubamatamab (DRUG), Fianlimab (DRUG).
Who is sponsoring clinical trial NCT06787612?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06787612 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06787612's enrollment target sits among peer trials
220 88th of 322 higher than 233 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
RECRUITING · Phase 2
-
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
RECRUITING · Phase 2
-
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00920972 · 220 participants · Phase 1
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
- NCT01851642 · 220 participants
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
- NCT02582021 · 220 participants
WISE CVD - Continuation (WISE HFpEF)
- NCT04067830 · 220 participants · Phase 2
Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI